PDCD1 and neoplasm: The results of this study are largely consistent with published reports, suggesting that administering probiotics (Probio-M9 in this case) promoted the antitumor immune response in anti-PD-1-based therapy by enhancing the beneficial bacteria while suppressing the harmful ones in antibiotic-treated tumor-bearing mice (Figure 5).